Clinical Trial

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
Trial Details
NCT Number NCT06901622
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Enrollment 50 participants
Start Date 2024-11-08
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-30